FDA Grants Third Approval Under National Priority Voucher Program For Tec-Dara

05 Mar 20264 min read0 views

GIST

The FDA has approved teclistamab in combination with daratumumab hyaluronidase-fihj (Tec-Dara) for adults with relapsed or refractory multiple myeloma who have received at least one prior therapy. The decision, made 55 days after filing, represents the third approval issued under the Commissioner’s National Priority Voucher pilot program.

A voucher was awarded to the sponsor in December 2025 after a Phase 3 trial indicated Tec-Dara improved progression-free survival and overall survival versus standard of care, with an 83% relative reduction in risk of progression or death. The program aims to accelerate approvals for therapies addressing national health priorities and large unmet needs, with vouchers offering benefits such as enhanced communications and expedited review.

The Phase 3 study also supported confirmatory evidence for Tecvayli (teclistamab-cqyv) monotherapy, transitioning its accelerated approval to traditional approval. Tecvayli carries boxed warnings for life-threatening or fatal cytokine release syndrome and immune effector cell–associated neurotoxicity, and Tec-Dara is available only under the Tecvayli-Talvey REMS.

Common Tec-Dara–related adverse events include hypogammaglobulinemia and infections, among others. Uncertainty remains regarding long-term outcomes beyond the reported trial results.

Clinical Editorial

Heading: Context and milestone for a novel combination therapy

The FDA has approved teclistamab in combination with daratumumab hyaluronidase-fihj (Tec-Dara) for adults with relapsed or refractory multiple myeloma who have received at least one prior therapy.
This approval represents the third authorization issued under the Commissioner’s National Priority Voucher (CNPV) pilot program, issued 55 days after submission.
The CNPV framework is designed to expedite approvals for therapies addressing high-priority national health needs, with selected companies receiving a voucher that can enable enhanced communications, rolling review, and shortened review timelines.

Heading: Evidence base underpinning the decision

The regulatory action followed a Phase 3 randomized trial in which Tec-Dara demonstrated improvements over the standard of care in progression-free survival and overall survival.
In the trial, Tec-Dara reduced the risk of disease progression or death by 83% relative to the control arm, indicating a substantial effect on the primary disease trajectory within the studied population.
Confirmatory evidence from the Phase 3 study additionally supported the existing indication for Tecvayli (teclistamab-cqyv) used as monotherapy, which will transition from accelerated approval to traditional approval based on these results.

Heading: Safety framework and risk management

Tecvayli, the monoclonal antibody component of the combination, carries a boxed warning highlighting life-threatening or fatal cytokine release syndrome (CRS) and neurologic toxicity, including immune effector cell-associated neurotoxicity (ICANS).
CRS is described as an inflammatory response that can present with high fever, hypotension, and, in severe cases, death.
Given these risks, Tec-Dara is accessible only through a restricted program under a REMS (Tecvayli-Talvey REMS) to ensure appropriate risk mitigation and monitoring.
The most frequently reported adverse events with Tec-Dara include hypogammaglobulinemia, upper respiratory infections, cough, diarrhea, musculoskeletal pain, COVID-19, pneumonia, injection-site reactions, fatigue, fever, headache, nausea, gastroenteritis, and weight changes.

Heading: Operational and programmatic implications

The approval decision showcases a proactive FDA stance to shorten idle time between discovery and patient access for therapies aligned with national priorities.
The CNPV program aims to accelerate access to innovative therapies, address large unmet needs, support domestic manufacturing, and potentially enhance affordability through expedited pathways.
Leadership comments emphasize the agency’s aim to translate compelling second-line myeloma trial results into timely availability for patients facing the disease.

Heading: Regulatory and clinical context

The Tec-Dara indication adds to the regulatory portfolio surrounding teclistamab, with the combination therapy now assessed in a relapsed/refractory setting following prior lines of therapy.
The current labeling carries a REMS requirement to address CRS and neurotoxicity risks, reflecting ongoing safety considerations for dual-targeted immune-based regimens.
The agency’s communications underscore that the approval process integrated results from a robust Phase 3 trial and leveraged the CNPV framework to achieve a more expedient review timeline.

Heading: Limitations and uncertainties in the source

The provided material does not present numerical outcomes beyond the stated 83% risk reduction in progression or death, nor does it detail the exact patient population size, prior lines of therapy distributions, or follow-up duration.
Specific comparative metrics such as absolute survival gains, quality-of-life measures, or long-term safety signals beyond the listed adverse events are not described in the supplied content.
As a result, precise interpretation of magnitude beyond the reported relative risk reduction and the general safety profile should be considered within the constraints of the summarized source.

Heading: Open questions and practical considerations for practice

How the Tec-Dara combination will integrate with existing front-line and relapsed strategies in diverse real-world settings remains to be clarified from additional data and post-approval experience.
The real-world safety experience with the REMS framework for Tec‑Vayli-containing regimens in combination contexts warrants ongoing surveillance.
The extent to which the CNPV mechanism translates into timely patient access across different therapeutic areas will depend on future project selections and agency workflows, as described in the program overview.